BioNTech Vaccine Treats MS in Mice Without Dampening Immune System
BioNTech’s experimental non-inflammatory vaccine — designed to dampen the abnormal immune responses seen in multiple sclerosis (MS) against myelin — delayed…
BTK Inhibitor Fenebrutinib Aims to Tackle Progressive MS in FENtrepid Trial
August 20, 2021 – Marco Meglio NeurologyLive, August 2021, Volume 4, Issue 4 The agent’s safety profile has been studied in…
Stuart Schlossman
6-Week Dosing of Natalizumab Effective, May Reduce PML Risk
August 3, 2021 – Abby Reinhard Efficacy data from a trial examining extended dosing adds to real-world data that demonstrates…
Stuart Schlossman
Efficacy of probiotics in multiple sclerosis: a systematic review of preclinical trials and meta-analysis of randomized controlled trials
Jinchi Jiang,‡a Chuanqi Chu,‡a Caie Wu,b Chen Wang,ac Chengcheng Zhang,ac Tiantian Li,ac Qixiao Zhai, acd Leilei Yu,*ac Fengwei Tian *ac and Wei Chen acef Author affiliations Abstract Preliminary evidence shows the potential role…
Stuart Schlossman
Study protocol on advance care planning in multiple sclerosis (ConCure-SM): intervention construction and multicentre feasibility trial
August 13, 2021 – Pubmed Abstract Introduction: Multiple sclerosis (MS) is the most common cause of progressive neurological disability in young…
Stuart Schlossman
What is happening to people with MS on DMTs getting vaccinated with the COVID-19 vaccines. Are they immune or not?
Gavin Giovannoni Jul 16 Yes, we are seeing vaccine breakthroughs in vaccinated patients with MS on ocrelizumab. A colleague…
Stuart Schlossman
Trial Will Test Mavenclad for Advanced Progressive MS
After some delays due to the COVID-19 pandemic, the Phase 2/3 clinical trial evaluating whether Mavenclad (cladribine) can slow hand and arm…
Stuart Schlossman
Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls
Enrique Alvarez 1, Kavita V Nair 2, Brian D Hoyt 3, Rebecca A Seale 1, Stefan Sillau 1, Augusto Miravalle 4, Eric Engebretson 1, Brittany Schurr 1, John R Corboy 1, Timothy L Vollmer 1, Justin M Honce 5 Affiliations …
Stuart Schlossman
Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
AUGUST 2, 2021 • Results show that every six-week natalizumab IV administration…
Stuart Schlossman
Could BTK Inhibitors Be the Next Big MS Treatment?
by Ed Tobias | July 30, 2021 – The MS Wire Is orelabrutinib one of the next big MS therapies? Biogen…
Stuart Schlossman
